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Summary
Objective: To compare the effects of glucosamine (GlcN), curcumin, and diacerein in immortalized human C-28/I2 chondrocytes at the cellular
and the gene expression level. This study aimed to provide insights into the proposed beneﬁcial effects of these agents and to assess the
applicability of the C-28/I2 cell line as a model for the evaluation of chondroprotective action.
Methods: Interleukin-1beta (IL-1b)-stimulated C-28/I2 cells were cultured in the presence of GlcN, curcumin, and diacerein prior to the
evaluation of parameters such as viability, morphology and proliferation. The impact of GlcN, curcumin, and diacerein on gene expression
was determined using quantitative real-time RT-PCR (qPCR).
Results: At the transcriptional level, 5 mM GlcN and 50 mM diacerein increased the expression of cartilage-speciﬁc genes such as aggrecan
(AGC) and collagen type II (COL2), while reducing collagen type I (COL1) mRNA levels. Moreover, the IL-1b-mediated shift in gene expres-
sion pattern was antagonized by GlcN and diacerein. These effects were associated with a signiﬁcant reduction in cellular proliferation and the
development of chondrocyte-speciﬁc cell morphology. In contrast, curcumin was not effective at lower concentrations but even damaged the
cells at higher amounts.
Conclusions: Both GlcN and diacerein promoted a differentiated chondrocytic phenotype of immortalized human C-28/I2 chondrocytes by
altering proliferation, morphology, and COL2/COL1 mRNA ratios. Moreover, both agents antagonized inhibitory effects of IL-1b by enhancing
AGC and COL2 as well as by reducing COL1 mRNA levels.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is a chronic, degenerative joint disorder
characterized by enhanced degradation of major extracellu-
lar matrix (ECM) components as well as by extensive
changes in the types and amounts of newly synthesized
ECM molecules1,2. To date, OA represents a non-curable
disease and classic therapeutic approaches are limited to
symptom-relieving drugs or surgical intervention. Chondro-
protection with drugs possessing disease-modifying quali-
ties represents an alternative concept in the treatment of
OA aiming to intervene therapeutically in the course of
cartilage degradation with pharmacological agents3.
Glucosamine (GlcN), curcumin, and diacerein are examples
of such chondroprotective agents (CPA). Studies performed*Address correspondence and reprint requests to: Dr Stefan
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1205both in vitro and in vivo, however, have yielded partially
inconsistent ﬁndings4e12. Although medical opinion about
the applicability and clinical efﬁcacy of CPA in OA remains
controversial, these agents are widely available and gener-
ally well tolerated and may possess more desirable safety
proﬁles as compared to non-steroidal anti-inﬂammatory
drugs (NSAIDs). A detailed clariﬁcation of the molecular
effects of CPA is therefore regarded as important for our
understanding of OA modifying action.
For the investigation of chondroprotective action, interleu-
kin-1beta (IL-1b)-stimulated chondrocyte models represent
a helpful tool5,7,8,12e14. In these models, cultured chondro-
cytes are incubated with both an inﬂammatory mediator
such as IL-1b and the CPA of interest, prior to the investiga-
tion of selected targets at the protein or gene expression
level. However, it is well known that studies using primary
cultures of human articular chondrocytes suffer from numer-
ous limitations such as poor yields, little proliferative activity,
and inter-individual variability of donor samples. In order to
circumvent these drawbacks, the human chondrocyte cell
line C-28/I2 was established by retroviral-mediated trans-
fection of primary rib chondrocytes with the large T antigen
1206 S. Toegel et al.: Chondroprotection in C-28/I2 cellsof Simian Virus 4015. C-28/I2 cells have been shown to re-
tain chondrocytic morphology, to maintain continuous
proliferation in monolayer culture and to express well-
differentiated chondrocyte-speciﬁc genes, particularly ma-
trix-anabolic and matrix-catabolic genes. In recent studies,
C-28/I2 cells have been used to investigate chondrocytic
response to IL-1b, nitric oxide, hyaluronan oligosaccha-
rides, or oxygen species16e18. To date, only one study
has been published that reported the application of C-28/
I2 cells for the evaluation of chondroprotective effects using
extracts of Schisandra fructus19. Therein, Choi et al.
observed protective effects of herbal components on aggre-
can (AGC) expression against hyaluronidase treatment.
From this background, the present study aimed to
compare the chondroprotective activities of GlcN, curcumin,
and diacerein in immortalized human chondrocytes. IL-
1b-challenged C-28/I2 chondrocytes were cultured in the
presence of GlcN, curcumin, or diacerein and parameters
such as viability, morphology, and proliferation were
assessed. In addition, mRNA levels of both anabolic and
catabolic marker genes were determined using quantitative
real-time RT-PCR (qPCR). Our results will provide insights
into the proposed beneﬁcial effects of GlcN, curcumin, and
diacerein and information on the applicability of IL-1b-
stimulated C-28/I2 cells as a model for evaluating chondro-
protective action.Materials and methodsMATERIALSGlcN, curcumin, diacerein, trypsin-ethylene diamine tetraacetic acid
(EDTA), ﬂuorescein diacetate (FDA) and ethidium bromide (EB) were pur-
chased from Sigma (St. Louis, MO, USA). Recombinant human IL-1b was
obtained from Strathmann (Hamburg, D). qPCR primers were from Metabion
(Martinsried, D). Dulbecco’s modiﬁed Eagle’s medium (DMEM) and insulin-
transferrin-selenium-solution (ITS) were purchased from Gibco (Lofer, A).
The StrataScript First-Strand Synthesis System and the Brilliant SYBR
Green QPCR Master Mix were from Stratagene (La Jolla, CA, USA).CELL CULTURETable IImmortalized C-28/I2 chondrocytes, previously described by Goldring
et al.15, were used throughout the study. Cells were seeded at 9.3 103 cells
per cm2 and cultured using DMEM supplemented with 10% fetal calf serum
(Biochrom AG, Berlin, D), 2 ml/ml gentamycin, and 50 mg/ml ascorbate as cul-
ture medium. Upon conﬂuence, cells were split using 0.03% trypsin-EDTA
and seeded at the same density for viability, morphology, proliferation, and
qPCR assays. GlcN was dissolved in culture medium, whereas curcumin
and diacerein were dissolved in 96% ethanol and >99.9% dimethyl sulfoxide
(DMSO), respectively, prior to addition to the medium.Experimental condit ions for qPCR experiments. Medium
supplements were added to the chondrocyte culture medium atCELL VIABILITY AND CELL MORPHOLOGY
the following concentrations: IL-1b, 10 ng/ml recombinant human
IL-1b; [c]1, low concentration of GlcN (50 mM), curcumin (5 mM) or
diacerein (5 mM); [c]2, high concentration of GlcN (5 mM), curcumin
(50 mM) or diacerein (50 mM)
Experimental condition Supplements on days of culture
Day 5 Day 6
Control e e
IL-1b e IL-1b
Simultaneous incubation
with CPA [c]1
e [c]1þ IL-1b
Simultaneous incubation
with CPA [c]2
e [c]2þ IL-1b
Pre-incubation [c]1 [c]1þ IL-1bChondrocytes were cultured to conﬂuence on glass cover slips. The
conﬂuent stage was selected to provide a reproducible stage of cell culture
for all assays. Cell monolayers were challenged with either 10 ng/ml IL-1b,
5 mM GlcN, 5 mM curcumin, 50 mM curcumin, or 50 mM diacerein. Untreated
cells served as control representing viable cells. After 24 h, the cell culture
medium was removed and 400 ml dying solution containing 8 mg/ml FDA
and 10 mg/ml EB in PBS were added to each well. After 5 min, cells were
inspected using a Nikon Eclipse 50i microscope equipped with an EXFO
X-Cite 120 ﬂuorescence illumination system. Using the ImageJ 1.36b
software, the percentage of EB-stained cells was calculated with respect
to methanol (MeOH)-treated cells (50 ml MeOH; 5 min; 20C) representing
100% dead cells.
In addition, morphological alterations of C-28/I2 cells upon treatment with
10 ng/ml IL-1b, 5 mM GlcN, 5 mM curcumin, and 50 mM diacerein were
observed using light microscopy.with CPA [c]1
Pre-incubation [c]2 [c]2þ IL-1bPROLIFERATION ASSAY
with CPA [c]2
CPA only [c]2 [c]2Chondrocytes were grown to conﬂuence in 96-well microplates (Iwaki,
Tokyo, Japan). Then, culture medium supplemented with either 10 ng/mlIL-1b, 10 ng/ml IL-1b and 5 mM GlcN, 10 ng/ml IL-1b and 5 mM curcumin,
or 10 ng/ml IL-1b and 50 mM diacerein was added. Cultures without IL-1b
and CPA were used as controls. After 24 h, the quantity of total cells was de-
termined using the CyQuant assay (Molecular Probes, Eugene, OR, USA)
pursuing a modiﬁed protocol20. The rate of proliferating cells was assessed
by incorporation of 2-bromodesoxyuridine into the DNA of dividing cells using
the colorimetric BrdU assay (Roche, Mannheim, Germany).EXPERIMENTAL CONDITIONS FOR qPCROn days 5 and 6 after seeding into 25 cm2 culture ﬂasks (Corning, NY,
USA), cells were exposed to serum-free ITS medium supplemented with
the particular CPA (GlcN, curcumin, or diacerein) and/or IL-1b (10 ng/ml)
as indicated in Table I. Seven conditions for each CPA experiment were
created: one control group without additional supplements, one IL-1b treated
group, two groups simultaneously treated with both IL-1b and the CPA at two
different concentrations, two groups pre-incubated with the CPA at two differ-
ent concentrations prior to IL-1b addition, and one group treated with the
respective CPA at the higher concentration without the addition of IL-1b.
Each of these study groups consisted of three identically treated biological
replicates.
On day 7 after seeding, total RNA was extracted using the NucleoSpin
RNA II Kit (Macherey-Nagel, Dueren, D). All RNA samples were qualitatively
assessed on agarose gels and quantiﬁed using the Quant-It RiboGreen
reagent (Molecular Probes, Eugene, OR, USA) and the Stratagene MxPro
QPCR software. Reverse transcription (RT) into cDNA was performed using
the StrataScript First-Strand Synthesis System. Brieﬂy, 2 mg of total RNA
were reverse transcribed in a 20 ml reaction volume using oligo(dT) primers.
All cDNA preparations were diluted at a ratio of 1:10 with RNase free water
prior to qPCR.OPTIMIZATION OF qPCR ASSAYSPrimers for AGC, collagen type II (COL2) and collagen type I (COL1), ma-
trix metalloproteinase 3 (MMP3), ‘‘A distingegrin and metalloproteinases with
thrombospondin type 1 motif’’ (ADAMTS4) and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) were designed using the AlleleID 2.01 software
(Premier Biosoft, CA, USA). Sequences are listed in Table II. Primers for
beta-2-microglobulin (B2M) and hypoxanthine phosphoribosyl-transferase I
(HPRT1) were used as previously described21,22.
Primer concentrations for the qPCR experiments were optimized using
a matrix of forward and reverse primers varying in concentration from 50
to 900 nM and a puriﬁed PCR product as template21. Ampliﬁcation efﬁcien-
cies for each primer pair were derived from standard curves using dilution
series of a control cDNA sample. Both optimized primer concentrations
and ampliﬁcation efﬁciencies are listed in Table II.qPCRAll qPCR reactions were performed in 25 ml reaction mixtures containing
1 ml cDNA, 12.5 ml Brilliant SYBR Green qPCR Master Mix, primer pairs as
listed in Table II, and nuclease-free water to 25 ml. Each biological replicate
was run in duplicate on an Mx3000P qPCR system. Thermocycling
Table II
Sequences, optimal concentrations and amplification efficiencies of qPCR primers. In order to avoid non-specific product formation, primers
were designed to span introns and with minimized self and cross dimer DG values. Additionally, BLAST analyses were performed to verify
specificity
Gene symbol Primer sequences nM Efﬁciency (%)
AGC Fw: ACTGGCGAGCACTGTAAC 300 98.6
Rv: TCTTGGGCATTGTTGTTGAC 900
COL2 Fw: TGGTGGAGCAGCAAG 600 92.4
Rv: GGGAGGCGTGAGGTCTTCTG 600
COL1 Fw: CACTGGTGATGCTGGTCCTG 600 89.2
Rv: CGAGGTCACGGTCACGAAC 300
MMP3 Fw: GGTGTGGAGTTCCTGATGTTG 100 99.9
Rv: AGCCTGGAGAATGTGAGTGG 100
ADAMTS4 Fw: ACCCAAGCATCCGCAATCC 100 90.1
Rv: GCCCACATCAGCCATACCC 100
GAPDH Fw: GGAGTCCACTGGCGTCTTCAC 300 94.0
Rv: GAGGCATTGCTGATGATCTTGAGG 600
1207Osteoarthritis and Cartilage Vol. 16, No. 10conditions for AGC, COL1, MMP3, and ADAMTS4 consisted of an initial
polymerase activation step at 95C for 10 min, followed by 45 cycles at
95C for 30 s, at 55C for 1 min, and at 72C for 1 min. Thermocycling con-
ditions for COL2 were optimized and consisted of an initial polymerase acti-
vation step at 95C for 10 min, followed by 45 cycles at 95C for 30 s, at
58C for 45 s, and at 80C for 1 min. Afterwards, melting curves were gener-
ated to conﬁrm a single gene-speciﬁc peak and to detect primeredimer for-
mation. No-template controls were included in each run to control for
contaminations.DATA NORMALIZATION AND STATISTICSBased on our previous report addressing the importance of reference
gene selection in qPCR, gene expression data of AGC, COL1, and COL2
were normalized against GAPDH as single reference gene21. In order to
visualize up- and down-regulation of ECM-related genes in the ﬁgures
more clearly, expression levels were log-transformed (log base of 2) and
alterations with respect to the control group were displayed as log-fold
changes. Consequently, a log-fold change of 1 in the ﬁgures corresponds
to a two-fold alteration in relative quantity of mRNA levels. In contrast,
a log-fold change of 1 corresponds to a 0.5-fold alteration in relative quan-
tity (equivalent to a 50% reduction). Ratios of mRNA levels of COL2 to
COL1 (COL2/COL1) were calculated as ‘differentiation index’ according to
Ref. 2. Data of the MMP3 and ADAMTS4 experiments were normalized
using normalization factors derived from the geometric mean of GAPDH,
B2M, and HPRT1 and the geNorm software21,22. mRNA levels of MMP3
and ADAMTS4 in the samples were displayed as relative quantities with
respect to the untreated control group. Statistics were performed usingFig. 1. (A) Viability of C-28/I2 chondrocytes in response to CPA. Viable
whereas EB-stained red cell nuclei indicate damaged cells (A3, A4). Qua
(B) Morphological changes of C-28/I2 chondrocytes in response to CPA
and photographs were obtained via opticone-way analysis of variance (ANOVA) with post-hoc Tukey tests cross-
comparing all study groups (P< 0.05). Statistics of the viability and prolifer-
ation data were performed using the Student’s t test (P< 0.05).ResultsCELL VIABILITY AND MORPHOLOGYFigure 1(A) shows the viability of chondrocytes in
response to CPA treatment. Untreated control cells hydro-
lyzed the FDA reagent resulting in an intense green staining
(Fig. 1-A1). Similar results were obtained after exposure of
cells to 10 ng/ml IL-1b, 5 mM GlcN, 50 mM diacerein, or
5 mM curcumin (Fig. 1-A2). Whereas all other culture condi-
tions evoked minor staining with EB indicating a high rate of
viability (Fig. 1-A3), incubation of chondrocytes with 50 mM
curcumin resulted in intensive red staining of cell nuclei
with EB (Fig. 1-A4) indicating the presence of damaged
cells. Moreover, those cells became partly detached
from the cover slips. Graphical evaluation of cellular
viability yielded an area of dead cells of 59.2 3.4% in
case of MeOH-treated cells (representing 100% dead cells).
Compared to the untreated control prepared with PBScells appear green due to hydrolysis of the FDA reagent (A1, A2)
ntitative results of the image analysis are described in the Results.
or IL-1b. The substances were added to conﬂuent cell monolayers
al microscope after 48 h exposure.
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1208 S. Toegel et al.: Chondroprotection in C-28/I2 cells(4.6 1.1%), incubation with 10 ng/ml IL-1b, 5 mM
GlcN, 50 mM diacerein, or 5 mM curcumin yielded no sig-
niﬁcant differences (<6.5% dead cells). In contrast, treat-
ment of chondrocytes with 50 mM curcumin resulted in
42.9 8.4% dead cells.
Figure 1(B) shows the cell morphology of C-28/I2
chondrocytes under IL-1b or CPA exposure. Without CPA
or under treatment with IL-1b the cells of the conﬂuent
monolayers had a polygonal morphology (Fig. 1-B1 and
B2). No alteration was observed after treatment with 5 mM
curcumin (not shown). However, upon incubation with
5 mM GlcN or 50 mM diacerein a larger fraction of cells
was characterized by the chondrocyte-speciﬁc ‘spherical’
morphology (Fig. 1-B3 and B4).-0.5
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COL1The results of the CyQuant and the BrdU assays are
presented in Fig. 2 as percentages of either total cell count
or the number of proliferating cells with respect to the un-
treated control representing 100%. The results demonstrate
that neither of the treatments had a signiﬁcant impact on the
total number of cells. Regarding the proliferative activity,
neither IL-1b nor 5 mM curcumin signiﬁcantly inﬂuenced
this parameter. The absent effect of IL-1b on C-28/I2 cell
proliferation is contradictory to the behavior of primary chon-
drocytes and might represent a special feature of C-28/I2
chondrocytes, presumably attributed to their immortalized
character. Interestingly, the addition of 5 mM GlcN or
50 mM diacerein resulted in a signiﬁcant 20.6% and 14.1%
decrease of proliferating cells, respectively.Culture conditions
Fig. 3. Regulation of AGC, COL2, and COL1 mRNA expression by
EFFECTS OF IL-1b AT THE mRNA LEVELIL-1b and/or GlcN added to C-28/I2 chondrocytes under various
culture conditions (Table I). Signiﬁcant differences as compared
to the IL-1b treated group are marked with asterisks (P< 0.05). Sig-
niﬁcant dose-related differences between study groups (Table I)
are marked with brackets.The effects of IL-1b on the expression of ECM-associated
genes are depicted in Figs. 3e5 representing three
independent experiments. A high concentration of IL-1b
(10 ng/ml) was used to assure a maximal osteoarthritic
effect in chondrocytes in vitro23. Incubation of C-28/I2 cells
with IL-1b for 24 h resulted in 0.75-fold (0.41-log fold;
Fig. 3), 0.57-fold (0.82-log fold; Fig. 4), and 0.63-fold0
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Fig. 2. Total cell count and proliferative activity of C-28/I2 cells after
incubation with IL-1b and/or 5 mM GlcN, 5 mM curcumin, or 50 mM
diacerein. The number of total cells and proliferating cells was de-
termined using CyQuant and BrdU assays, respectively. Values of
the untreated control group were set to 100% and the inﬂuence of
IL-1b, GlcN, curcumin, and diacerein was calculated with regard to
this benchmark. Signiﬁcant differences as compared to the
untreated control are marked with asterisks (P< 0.05).(0.66-log fold; Fig. 5) decreased AGC mRNA levels.
Signiﬁcant suppression of COL2 mRNA levels was
observed in all experiments [from 0.68-fold (0.54-log
fold; Fig. 3) to 0.49-fold (1.01-log fold; Fig. 5)]. In contrast,
levels of COL1 were up-regulated 1.55-fold (0.64-log fold),
1.51-fold (0.60-log fold) and 1.68-fold (0.75-log fold) in
the three experiments, respectively. Regarding catabolic
marker genes, we found that IL-1b did not induce any
signiﬁcant change in either MMP3 or ADAMTS4 expression
in C-28/I2 chondrocytes (Table III).EFFECTS OF GlcN AT THE mRNA LEVELFigure 3 shows the inﬂuence of GlcN on mRNA levels of
AGC, COL2, and COL1 in C-28/I2 chondrocytes. The
graphs visualize that the incubation of chondrocytes with
5 mM GlcN for 48 h without adding IL-1b (‘GlcN only’)
induced contrary effects to those of IL-1b in case of AGC
and COL1. While AGC mRNA levels were up-regulated
4.6-fold (2.2-log fold) by GlcN, COL1 expression was
decreased to a signiﬁcant extent (0.31-fold; 1.71-log
fold). In contrast, 5 mM GlcN did not alter COL2
expression.
Of note, GlcN was found to antagonize the effects of IL-
1b in a dose-dependent manner. In this context, the
inhibitory effect of IL-1b on AGC was reversed by 5 mM
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Fig. 4. Regulation of AGC, COL2, and COL1 mRNA expression by
IL-1b and/or curcumin added to C-28/I2 chondrocytes under vari-
ous culture conditions (Table I). Signiﬁcant differences as com-
pared to the IL-1b treated group are marked with asterisks
(P< 0.05). Signiﬁcant dose-related differences between study
groups (Table I) are marked with brackets.
1209Osteoarthritis and Cartilage Vol. 16, No. 10GlcN in both the simultaneous-addition (‘sim_c2’) and pre-
incubation (‘pre_c2’) experiments resulting in a 1.25-fold
(0.32-log fold) and 1.8-fold (0.85-log fold) AGC up-
regulation, respectively. Regarding COL2 mRNA expres-
sion, addition of 5 mM GlcN (‘sim_c2’ and ‘pre_c2’)
reversed the action of IL-1b and increased COL2 levels to
values comparable to those of the untreated control.
Moreover, a comparison between 50 mM and 5 mM GlcN re-
vealed a signiﬁcant and dose-dependent down-regulation of
COL1 in both the simultaneous-addition and pre-incubation
experiments.
As shown in Table III GlcN did not regulate the transcrip-
tion of MMP3 and ADAMTS4 to a signiﬁcant extent.EFFECTS OF CURCUMIN AT THE mRNA LEVELThe inﬂuence of curcumin on ECM-related genes in C-28/
I2 cells is presented in Fig. 4. Curcumin (5 mM) e a concen-
tration that did not affect viability or proliferation of C-28/I2
cells e was not effective in preventing IL-1b-mediated
down-regulation of AGC or COL2 in either the simulta-
neous-addition (‘sim_c1’) or the pre-incubation experiments
(‘pre_c1’).Despite the damaging effects of 50 mM curcumin on C-28/
I2 cell viability (Fig. 1), we were interested in how this pro-
cess might be reﬂected at the level of gene expression. In-
terestingly, incubation of chondrocytes with 50 mM curcumin
for 48 h (‘curcumin only’) provoked a 4.2-fold (2.07-log fold)
increase of COL2 and a 0.38-fold (1.39-log fold) decrease
in COL1 expression as compared to the untreated control
group. In addition, the presence of 50 mM curcumin remark-
ably increased the expression of both MMP3 (2175.5-fold)
and ADAMTS4 (119.7-fold) (Table III).EFFECTS OF DIACEREIN AT THE mRNA LEVELThe supporting effect of diacerein on chondrocytic differ-
entiation was demonstrated by 3.19-fold (1.16-log fold) and
1.84-fold (0.61-log fold) increased levels of AGC and COL2
expression, respectively, when cells were exposed to
50 mM diacerein for 48 h (‘diacerein only’) (Fig. 5). Under
the same conditions, transcription of COL1 was down-
regulated 0.13-fold (2.89-log fold).
Signiﬁcant dose-dependent effects of diacerein on AGC
and COL1 mRNA levels were observed when cells were
additionally exposed to IL-1b. Incubation of cells with
50 mM diacerein (‘c2’) reversed the IL-1b-mediated modu-
lations of AGC and COL1 in both the simultaneous-
addition and pre-incubation experiments, whereas 5 mM
(‘c1’) did not. However, 5 mM diacerein was effective in
reducing the cytokine-induced down-regulation of the
COL2 transcription.
Regarding its impact on catabolic marker genes, we
found that diacerein did not alter MMP3 and ADAMTS4
mRNA levels signiﬁcantly as compared to untreated
controls (Table III).DiscussionGlcN AND DIACEREIN PROMOTE THE CHONDROCYTIC
PHENOTYPE OF C-28/I2 CELLSIn their natural surroundings chondrocytes exhibit low
mitotic activity and maintain the cartilage function by
synthesis of ECM-related proteins such as COL2 or AGC.
During in vitro expansion in monolayers, however, primary
chondrocytes have the tendency to dedifferentiate towards
a ﬁbroblast-like phenotype. Several studies have reported
that certain culture conditions can promote expansion of
primary chondrocytes but concomitantly induce dedifferen-
tiation24e28. The process of dedifferentiation is further
associated with modiﬁcations of the gene expression
pattern such as the decrease of COL2/COL1 mRNA ratios
and the loss of the round cell shape29. To overcome this
problem, various culture models have been developed
including cell pellet cultures or embedding in alginate
beads10,24,30,31. Although the use of immortalized chondro-
cyte cell lines in cartilage research has many advantages,
the culture of immortalized C-28/I2 cells in alginate beads
is limited as the proliferating cells form necrotic clusters
with reduced cytoplasm and die.
Here, we demonstrated that GlcN and diacerein can pro-
mote chondrocyte-speciﬁc characteristics of immortalized
C-28/I2 chondrocytes. The addition of 5 mM GlcN or
50 mM diacerein to the culture medium signiﬁcantly re-
duced the number of dividing cells. Viability, however,
was not affected. This process was further accompanied
by the formation of a ‘spherical’ cell morphology which is
known to be chondrocyte-speciﬁc32. In contrast, incubation
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Fig. 5. Regulation of AGC, COL2, and COL1 mRNA expression by
IL-1b and/or diacerein added to C-28/I2 chondrocytes under vari-
ous culture conditions (Table I). Signiﬁcant differences as com-
pared to the IL-1b treated group are marked with asterisks
(P< 0.05). Signiﬁcant dose-related differences between study
groups (Table I) are marked with brackets.
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rate of proliferation nor modulated the cell morphology.
These results are in agreement with our ﬁndings on gene
expression. Using qPCR, both GlcN and diacerein were
shown to be effective in promoting the mRNA expression
of the chondrocytic marker AGC. However, GlcN e at a con-
centration (5 mM) being 100-fold higher than diacerein
(50 mM) e induced a 44% higher up-regulation of AGC
as compared to diacerein (4.6-fold vs 3.19-fold up-regula-
tion). Moreover, COL2/COL1 ratios e previously deﬁned
as index of cell differentiation2 e were determined.
Whereas 5 mM curcumin did not inﬂuence the COL2/Table I
mRNA levels of MMP3 and ADAMTS4 in C-28/I2 chondrocytes treated w
presented as relative quantities as compared to the untreated control grou
the geometric mean of GAPDH, B2M, and HPRT1 by the geNorm software
the control group
Control IL-1b
MMP3 1.00 0.29 0.92 0.27
ADAMTS4 1.00 0.17 1.23 0.65COL1 ratio signiﬁcantly, the treatment with 5 mM GlcN re-
sulted in 4.5-fold increased values (0.18 0.03; P< 0.05)
as compared to the control samples (0.04 0.02). In com-
parison, the presence of 50 mM diacerein increased the
COL2/COL1 ratio in C-28/I2 chondrocytes 9.5-fold (from
0.0008 8.1 105 in the control samples to 0.0076
0.0011 in the challenged samples; P< 0.05).
All in all, our ﬁndings suggest that GlcN and diacerein can
induce a shift of immortalized C-28/I2 cells towards a more
chondrocytic phenotype.GlcN AND DIACEREIN ANTAGONIZE IL-1b-MEDIATED
EFFECTS IN C-28/I2 CELLSIt is well known that cytokines such as tumor necrosis
factor-alpha (TNF-a) or IL-1b contribute to the progress of
cartilage degradation in OA1. In the present study, we have
investigated and compared the ability of GlcN, curcumin,
and diacerein to antagonize the action of IL-1b in C-28/I2
chondrocytes at the mRNA level. When added to the culture
medium simultaneously with IL-1b, both GlcN and diacerein
dose-dependently reduced the impact of the cytokine. At
lower concentrations neither agent was chondroprotective
on COL1 or AGC mRNA expression. Regarding COL2 tran-
scription, however, 5 mM diacerein evoked a signiﬁcant up-
regulation whereas 50 mM GlcN were ineffective. At higher
concentrations (5 mM GlcN and 50 mM diacerein) both sub-
stances signiﬁcantly antagonized the effects of IL-1b. When
added simultaneously with IL-1b, 5 mM GlcN increased
AGC levels by 78% as compared to IL-1b treated cells,
whereas 50 mM diacerein induced an enhancement by
87%. Regarding COL2 transcription, 5 mM GlcN and
50 mM diacerein induced 37% and 29% higher expression
levels, respectively. Moreover, IL-1b-stimulated COL1
levels were reduced by 84% when cells were exposed to
50 mM diacerein whereas there was no signiﬁcant reduction
in presence of 5 mM GlcN.
Taken together, our ﬁndings suggest that both GlcN and
diacerein can prevent or reduce the IL-1b-induced inhibition
of ECM synthesis. However, diacerein appeared to be more
effective than GlcN since comparable or even better results
were obtained at much lower concentrations (5 mM GlcN vs
50 mM diacerein). This difference might be attributed to
different mechanisms of action12,33 and might be of interest
regarding the bioavailability of these agents after oral
administration.COMPARISON BETWEEN CHONDROPROTECTIVE EFFECTS
IN C-28/I2 CELLS AND PRIMARY CHONDROCYTESA further aim of this study was to evaluate the applicabil-
ity of the C-28/I2 cell line as a model for the investigation of
chondroprotective effects. Therefore, the ﬁndings of the
present report were compared to those of studies on
primary human chondrocytes in the literature. Indeed, our
results on GlcN are in agreement with a number of recentII
ith IL-1b or CPA (5 mM GlcN, 50 mM curcumin, or 50 mM diacerein),
p. Data were normalized using normalization factors calculated from
. Bold faced values indicate statistical significances as compared to
(P< 0.05)
GlcN Curcumin Diacerein
1.88 0.9 2175.5 484.3 1.79 0.38
2.65 1.32 119.7 25.4 1.96 1.33
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found that GlcN can stimulate mRNA levels of AGC,
whereas no substantial change in MMP3 levels was
induced. Another study using qPCR showed that 100 mM
and 1 mM GlcN maintained COL2 and stimulated AGC
gene expression in human OA chondrocytes after IL-1b ex-
posure6. Similar to our results, although using bovine chon-
drocytes, Varghese et al.33 found evidence for the relation
between GlcN-induced enhancement of matrix production
and concomitant inhibition of chondrocyte proliferation. In
addition, those authors also showed the correlation be-
tween a reduced proliferative activity upon GlcN exposure
and the appearance of a chondrocyte-speciﬁc ‘spherical’
morphology33.
Regarding the potential chondroprotective effects of
diacerein, studies have been conducted in both human
and animal cell culture systems10,12. Several mechanisms
of action have been discussed and consequences on the
production of speciﬁc matrix components have been sug-
gested34e36. To our knowledge, however, the present study
is the ﬁrst one demonstrating the ﬁnal impact of diacerein
on anabolic and catabolic marker gene transcriptions in
a human chondrocyte model. Comparable results were
reported by Martin et al.12 in a study on bovine chondro-
cytes using Northern blots in which 50 mM rhein, the active
metabolite of diacerein, enhanced mRNA levels of AGC
and COL2 and prevented the IL-1b-mediated inhibition of
synthesis of those matrix components.
In summary, our data from immortalized human chondro-
cytes are in line with the majority of in vitro studies suggest-
ing the efﬁciency of GlcN and diacerein to promote the
chondrocyte phenotype and to antagonize IL-1b effects on
ECM components. Given the reduced protein levels of
ECM components in C-28/I2 cells, studies on the protein
level demand for very sensitive assays including radiolabel-
ling37. Since such assays have not been performed in the
present study, conclusions regarding chondroprotective
effects of GlcN and diacerein on ECM proteins could not
be drawn. Even though recent studies have shown a direct
relationship between mRNA and protein levels of chondro-
cyte markers5,32,37, this lack of protein-related experiments
obviously represents a limitation of the present study. Based
on this report, the application of C-28/I2 cells for the evalua-
tion of chondroprotective action can only be suggested for
studies on chondrocyte markers at the mRNA level.
Moreover, the prediction of GlcN or diacerein-induced in
vivo effects based on any in vitro study has to be undertaken
with caution and evidence for clinical efﬁcacy has yet to be
strengthened.
Interestingly, our ﬁndings regarding the viability of chon-
drocytes in response to curcumin are contrary to a recent
study reporting that the treatment with 50 mM curcumin for
up to 48 h did not affect the viability of primary human
chondrocytes at the microscopic and ultra-structural level9.
In contrast, we found that this concentration severely
damaged the integrity of the C-28/I2 cell membrane and
induced cell detachment after 24 h incubation. It remains
to be clariﬁed whether this reduced viability in response to
50 mM curcumin represents a special feature of C-28/I2
cells. Noteworthy, the cellular stress caused by 50 mM cur-
cumin in C-28/I2 cells induced a shift in the gene expression
of collagen types resulting in 10-fold increased COL2/COL1
ratios (from 0.03 0.06 in the control samples to 0.3 0.03
in the challenged samples; P< 0.05). Of course, this appar-
ently beneﬁcial effect of curcumin is placed into perspective
not only by the observed cellular damage but also by the
aberrant expression of catabolic genes such as MMP3and ADAMTS4. Therefore, our study underlines the impor-
tance of interpreting qPCR results such as COL2/COL1
ratios in consideration of additional cellular parameters.
In summary, this is the ﬁrst study on a direct comparison
between in vitro effects of the frequently discussed CPA
such as GlcN, curcumin, and diacerein. In addition, the im-
pact of diacerein on anabolic and catabolic marker gene
transcriptions was presented for the ﬁrst time in a human
chondrocyte model. Both GlcN and diacerein promoted
a differentiated chondrocytic phenotype of immortalized
human C-28/I2 chondrocytes by altering proliferation, mor-
phology, and COL2/COL1 mRNA ratios. Moreover, both
agents antagonized inhibitory effects of IL-1b by enhancing
AGC and COL2 as well as by reducing COL1 mRNA levels.
In contrast, catabolic marker genes were not affected. Com-
pared to GlcN, diacerein was chondroprotective at much
lower concentrations which might be of interest regarding
the biopharmaceutical aspects of both drugs.
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